Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hdFMT and Pembrolizumab in R/R PD-L1+ NSCLC
NCT05669846Phase 2Recruiting
- Start
- Jan 2025
- Primary completion
- Dec 2036
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of Fecal Microbiota Transplantation capsules in non-small cell lung cancer (NSCLC). Started Jan 2025; status: recruiting.
02
Drugs
Fecal Microbiota Transplantation capsules
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05669846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669846.